Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

15 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The chemistry and biology of soluble guanylate cyclase stimulators and activators.
Follmann M, Griebenow N, Hahn MG, Hartung I, Mais FJ, Mittendorf J, Schäfer M, Schirok H, Stasch JP, Stoll F, Straub A. Follmann M, et al. Among authors: schirok h. Angew Chem Int Ed Engl. 2013 Sep 2;52(36):9442-62. doi: 10.1002/anie.201302588. Epub 2013 Aug 20. Angew Chem Int Ed Engl. 2013. PMID: 23963798 Review.
Discovery of riociguat (BAY 63-2521): a potent, oral stimulator of soluble guanylate cyclase for the treatment of pulmonary hypertension.
Mittendorf J, Weigand S, Alonso-Alija C, Bischoff E, Feurer A, Gerisch M, Kern A, Knorr A, Lang D, Muenter K, Radtke M, Schirok H, Schlemmer KH, Stahl E, Straub A, Wunder F, Stasch JP. Mittendorf J, et al. Among authors: schirok h. ChemMedChem. 2009 May;4(5):853-65. doi: 10.1002/cmdc.200900014. ChemMedChem. 2009. PMID: 19263460 Free article.
Discovery of the Soluble Guanylate Cyclase Stimulator Vericiguat (BAY 1021189) for the Treatment of Chronic Heart Failure.
Follmann M, Ackerstaff J, Redlich G, Wunder F, Lang D, Kern A, Fey P, Griebenow N, Kroh W, Becker-Pelster EM, Kretschmer A, Geiss V, Li V, Straub A, Mittendorf J, Jautelat R, Schirok H, Schlemmer KH, Lustig K, Gerisch M, Knorr A, Tinel H, Mondritzki T, Trübel H, Sandner P, Stasch JP. Follmann M, et al. Among authors: schirok h. J Med Chem. 2017 Jun 22;60(12):5146-5161. doi: 10.1021/acs.jmedchem.7b00449. Epub 2017 Jun 12. J Med Chem. 2017. PMID: 28557445 Free article.
Design and synthesis of potent and selective azaindole-based Rho kinase (ROCK) inhibitors.
Schirok H, Kast R, Figueroa-Pérez S, Bennabi S, Gnoth MJ, Feurer A, Heckroth H, Thutewohl M, Paulsen H, Knorr A, Hütter J, Lobell M, Münter K, Geiss V, Ehmke H, Lang D, Radtke M, Mittendorf J, Stasch JP. Schirok H, et al. ChemMedChem. 2008 Dec;3(12):1893-904. doi: 10.1002/cmdc.200800211. ChemMedChem. 2008. PMID: 18973168
Cardiovascular effects of a novel potent and highly selective azaindole-based inhibitor of Rho-kinase.
Kast R, Schirok H, Figueroa-Pérez S, Mittendorf J, Gnoth MJ, Apeler H, Lenz J, Franz JK, Knorr A, Hütter J, Lobell M, Zimmermann K, Münter K, Augstein KH, Ehmke H, Stasch JP. Kast R, et al. Among authors: schirok h. Br J Pharmacol. 2007 Dec;152(7):1070-80. doi: 10.1038/sj.bjp.0707484. Epub 2007 Oct 15. Br J Pharmacol. 2007. PMID: 17934515 Free PMC article.
Discovery of Rogaratinib (BAY 1163877): a pan-FGFR Inhibitor.
Collin MP, Lobell M, Hübsch W, Brohm D, Schirok H, Jautelat R, Lustig K, Bömer U, Vöhringer V, Héroult M, Grünewald S, Hess-Stumpp H. Collin MP, et al. Among authors: schirok h. ChemMedChem. 2018 Mar 6;13(5):437-445. doi: 10.1002/cmdc.201700718. Epub 2018 Feb 16. ChemMedChem. 2018. PMID: 29451369
Therapeutic efficacy of azaindole-1 in experimental pulmonary hypertension.
Dahal BK, Kosanovic D, Pamarthi PK, Sydykov A, Lai YJ, Kast R, Schirok H, Stasch JP, Ghofrani HA, Weissmann N, Grimminger F, Seeger W, Schermuly RT. Dahal BK, et al. Among authors: schirok h. Eur Respir J. 2010 Oct;36(4):808-18. doi: 10.1183/09031936.00140309. Epub 2010 Jun 7. Eur Respir J. 2010. PMID: 20530035 Free article.
15 results